Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental cancer drugs
Entospletinib
Другие языки:

    Entospletinib

    Подписчиков: 0, рейтинг: 0
    Entospletinib
    Entospletinib.svg
    Clinical data
    Other names GS-9973
    Legal status
    Legal status
    • Investigational
    Identifiers
    • 6-(1H-Indazol-6-yl)-N-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine
    CAS Number
    PubChem CID
    DrugBank
    UNII
    KEGG
    Chemical and physical data
    Formula C23H21N7O
    Molar mass 411.469 g·mol−1
    3D model (JSmol)
    • c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1
    • InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27)
    • Key:XSMSNFMDVXXHGJ-UHFFFAOYSA-N

    Entospletinib is an experimental drug for the treatment of various types of cancer under development by Gilead Sciences. It is an inhibitor of spleen tyrosine kinase (Syk). It has entered clinical trials for acute myeloid leukaemia (AML), chronic lymphocytic leukemia (CLL),diffuse large B cell lymphoma (DLBCL), graft-versus-host disease (GvHD), hematological malignancies, mantle cell lymphoma (MCL), and non-Hodgkin lymphoma (NHL).


    Новое сообщение